UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 23, 2016
TRACON Pharmaceuticals, Inc. |
(Exact name of registrant as specified in its charter) |
Delaware |
| 001-36818 |
| 34-2037594 |
(State or other jurisdiction |
| (Commission File Number) |
| (IRS Employer Identification No.) |
of incorporation) |
|
|
|
|
8910 University Center Lane, Suite 700 San Diego, California |
|
| |
(Address of principal executive offices) |
| (Zip Code) | |
|
| ||
Registrant’s telephone number, including area code: (858) 550-0780 | |||
|
| ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events.
On November 23, 2016, TRACON Pharmaceuticals, Inc. (“we” or “TRACON”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, as representative of the several underwriters named therein (the “Underwriters”), relating to the issuance and sale of 2,625,000 shares of our common stock, par value $0.001 per share. The price to the public in this offering was $5.75 per share. The gross proceeds to us from the sale of 2,625,000 shares in this offering are expected to be approximately $15.1 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering is scheduled to close on or about November 29, 2016, subject to customary closing conditions. In addition, under the terms of the Underwriting Agreement, we granted the Underwriters an option, exercisable for 30 days, to purchase up to 393,750 additional shares of common stock.
The Underwriting Agreement contains customary representations, warranties, covenants and agreements by us, customary conditions to closing, indemnification obligations of us and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties.
The offering was made pursuant to our effective registration statement on Form S-3 (Registration Statement Nos. 333-209313) previously filed with the Securities and Exchange Commission (“SEC”) and a related prospectus. The Underwriting Agreement is filed as Exhibit 1.1 to this report and the description of the terms of the Underwriting Agreement is qualified in its entirety by reference to such exhibit. A copy of the opinion of Cooley LLP relating to the legality of the issuance and sale of the shares in the offering is attached as Exhibit 5.1 hereto.
On November 22, 2016, we issued a press release announcing that we had commenced the offering. On November 23, 2016, we issued a press release announcing that we had priced the offering. Copies of these press releases are attached as Exhibits 99.1 and 99.2 hereto, respectively.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
| Description |
|
|
|
1.1 |
| Underwriting Agreement, November 23, 2016. |
|
|
|
5.1 |
| Opinion of Cooley LLP. |
|
|
|
23.1 |
| Consent of Cooley LLP (included in Exhibit 5.1). |
|
|
|
99.1 |
| Press release, dated November 22, 2016. |
|
|
|
99.2 |
| Press release, dated November 23, 2016. |
Forward-Looking Statements
Statements made in this report regarding matters that are not historical facts are “forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward‐looking statements. Such statements include, but are not limited to, statements regarding our expectations regarding the completion, timing and gross proceeds of our public offering. Risks that could cause actual results to differ from those expressed in these forward‐looking statements include: risks and uncertainties associated with the satisfaction of customary closing conditions related to the public offering and other risks described in our filings with the Securities and Exchange Commission under the heading “Risk Factors”. All forward‐looking statements contained in this report speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TRACON Pharmaceuticals, Inc.
| ||
Dated: November 23, 2016 |
By: |
/s/ Charles P. Theuer, M.D., Ph.D. |
|
|
| Charles P. Theuer, M.D., Ph.D. President and Chief Executive Officer
| |
EXHIBIT INDEX
Exhibit No. |
| Description |
|
|
|
1.1 |
| Underwriting Agreement, dated November 23, 2016. |
|
|
|
5.1 |
| Opinion of Cooley LLP. |
|
|
|
23.1 |
| Consent of Cooley LLP (included in Exhibit 5.1). |
|
|
|
99.1 |
| Press release, dated November 22, 2016. |
|
|
|
99.2 |
| Press release, dated November 23, 2016. |